Thieler Law Corp advises investors with losses exceeding $100,000 of the July 15, 2019 lead plaintiff deadline in a class action lawsuit filed against Intersect ENT Inc (NASDAQ: XENT) (“Intersect” or “the Company”). The suit is pending in the U.S. District Court for the Northern District of California and investors, who purchased Intersect ENT Inc securities between August 1, 2018 and May 6, 2019, have until July 15, 2019 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Intersect ENT Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Intersect lacked adequate reimbursement representatives to ensure physicians had access to SINUVA, Intersect’s sinus implant; Intersect’s sales force would focus on ensuring reimbursement; Intersect’s sales representatives were less focused on driving sales; physicians were less likely to adopt Intersect’s SINUVA due to transaction costs associated with seeking reimbursement; Intersect would increase staffing to address these issues; and as a result of the foregoing, defendants’ positive statements about Intersect’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On August 1, 2018, Intersect revealed that it faced certain challenges with the launch of INUVA, which had negatively impacted the Company’s second quarter 2018 financial results.

Following this news, NASDAQ: XENT fell $6.30, nearly 20%, to close at $26.05 per share on August 1, 2018.

On May 6, 2019, Intersect revealed a first quarter 2019 loss of $10.8 million and lowered guidance for the remainder of 2019. In Addition, the Company revealed that the Company’s CEO, resigned.

Following this news, NASDAQ: XENT fell $8.05, or more than 25%, to close at $25.10 per share on May 7, 2019.

If you were negatively impacted by your investment in Intersect ENT Inc securities between August 1, 2018 and May 6, 2019 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185